Sinocare présente ses produits pour la gestion du diabète et des maladies chroniques lors de la deuxième exposition économique et commerciale Chine-Afrique

CHANGSHA, Chine, 29 septembre 2021 /PRNewswire/ — Sinocare, le leader mondial du développement de tests médicaux, a présenté sa dernière gamme de produits lors de la deuxième exposition économique et commerciale Chine-Afrique (CAETE), qui s’est tenue du 26 au 29 septembre au centre international de congrès et d’expositions de Changsha. Sinocare a présenté, sur le stand qui lui était réservé, différents types de produits pour la gestion des maladies chroniques, notamment le glucomètre, le tensiomètre, le détecteur de lipides sanguins et le détecteur d’acide urique, et a également dévoilé son analyseur multifonction portable analyseur HbA1C portable et son détecteur par fluorescence de produits finis de glycation avancée.

Sinocare Headquarters

CAETE est une plate-forme importante pour la Chine et les pays africains pour mener une coopération économique et commerciale, et des échanges et dialogues intéressants. Sous le thème « Nouveau départ, nouvelles opportunités, nouvelles réalisations », l’événement de cette année est axé sur les domaines des produits alimentaires et agricoles, des industries médicales et de santé, de la coopération en matière d’infrastructures et de chaînes industrielles, ainsi que de la coopération économique et commerciale approfondie. Sinocare a présenté un certain nombre de produits de pointe qui favoriseront davantage la coopération entre les secteurs médical et de la santé de la Chine et de l’Afrique, et permettront la construction d’une communauté médicale commune.

« Chez Sinocare, notre vision consiste à fournir des produits et des services de haute qualité aux personnes souffrant de diabète et d’autres maladies chroniques afin de les aider à améliorer leur qualité de vie. Nous avons hâte de travailler avec des professionnels de santé et des entreprises privées en Afrique pour fournir à davantage de personnes des solutions accessibles et abordables pour la gestion du diabète », a déclaré Louis Hu, directeur régional de Sinocare pour l’Afrique.

Lors de la CAETE, Sinocare a lancé ses produits phares pour quatre maladies chroniques : le Gold AQ PLUS et le Safe AQ Smart pour la glycémie, l’AES-U111 pour la pression artérielle ; iCARE2100 pour l’analyse multi-index ; et PCH50 pour l’analyse de l’HbA1C. Avec des caractéristiques et des avantages notables, les produits de Sinocare ont attiré l’attention d’innombrables participants qui se sont arrêtés sur le stand pour une consultation.

Gold AQ PLUS possède des propriétés électrochimiques supérieures et une résistance à la corrosion extrêmement importante avec une bandelette de test d’électrode en or pur à 99,99%. Le système est capable de détecter avec précision la température de l’échantillon de sang, le HCT et la température ambiante, et de corriger automatiquement les écarts de résultat. Son autre glucomètre phare exposé était le Safe AQ Smart, doté d’un système FAD-GDH pour des résultats exacts et précis, d’un système d’exploitation facile d’utilisation qui ne nécessite aucun codage et d’une éjection automatique des bandelettes de test.

Pour les patients présentant un taux de cholestérol élevé, le détecteur de lipides et de glycémie à double usage peut être utilisé pour la mesure quantitative du CT, du HDL, des TG et du GLU. Le détecteur a un débit rapide de glucose en 5s et de lipides en 100s, et prend en charge l’impression en ligne par USB et la transmission de données par Bluetooth. Par ailleurs, le système de surveillance de la glycémie et de l’acide urique à double fonction Safe AQ-UG peut être utilisé pour les personnes souffrant de diabète et d’hyperuricémie. Safe AQ UG respecte la norme ISO15197 2013 et est équipé d’une éjection automatique des bandelettes et d’un code intelligent pour les tests d’acide urique.

En outre, iCARE2100 est l’instrument multiplateforme innovant de Sinocare possédant plusieurs indicateurs pour réaliser des tests pratiques au chevet du patient. Alimenté par la technologie principale Liquid Phase iPOCT, iCARE 2100 prend en charge une haute précision et une détection instantanée. Sans utiliser d’autres consommables, les praticiens peuvent réduire les coûts des tests sans compromettre la qualité.

Au-delà de la Chine, Sinocare est présent dans 42 pays d’Afrique, dont l’Algérie, l’Égypte, l’Éthiopie, l’Afrique du Sud et plus encore. L’ensemble de ses ventes à travers le continent ont atteint plus de 110 millions de yuans, les produits les plus populaires de Sinocare étant les systèmes de surveillance de la glycémie, les tensiomètres, les analyseurs de profil lipidique et les détecteurs de HbA1c. La croissance rapide de Sinocare en Afrique s’explique par ses systèmes indolores et faciles à utiliser qui conviennent à un grand nombre de personnes, ainsi que sa stabilité de prélèvement d’échantillons et de bandelette de test avec une technologie brevetée.

Sinocare continue de se développer activement en Afrique et prévoit de créer des usines de production en Algérie et en Égypte pour réaliser la production locale de bandelettes de test de glycémie. Cette initiative réduira considérablement les coûts et le temps de transport, et accélérera ses capacités à fournir aux populations africaines des produits pour la surveillance du diabète.

À propos de Sinocare : 

Sinocare compte 19 ans d’expérience dans le secteur des lecteurs de glycémie depuis sa fondation en 2002. La société se consacre au développement, à la production et à la vente de la détection rapide des maladies chroniques grâce à l’utilisation de la technologie des biocapteurs. En 2016, après avoir acquis avec succès Nipro diagnostic Inc. (maintenant renommée Trividia Health Inc.) et PTS Diagnostics Inc., Sinocare est devenu le numéro 5 mondial des fabricants de glucomètres et l’une des principales sociétés au monde d’appareils de test au point de service.

Pour plus d’informations, veuillez consulter le site : www.sinocareintl.com

Facebook : Sinocare In’tl 

Contact pour les médias : Echo Gao
[email protected]

Photo – https://mma.prnewswire.com/media/1637313/Sinocare_Headquarters.jpg

 

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular Injection in Ongoing Phase 2/3 Studies

Data to be Presented During IDWeek 2021 and 19th Annual Discovery on Target Conference

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the company’s COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the company’s ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America’s IDWeek 2021, being held from Sept. 29 – Oct. 3, 2021. In addition, Adagio’s chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19th Annual Discovery on Target Conference on Sept. 30, 2021.

“The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 – which was designed to be potent, broadly neutralizing and delivered as a single IM injection – could have on people with or at risk of COVID-19,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19. We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.”

Phase 1 Trial Update
Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. Importantly, ADG20 was well tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts. Participants will continue to be followed through 12 months to assess safety and tolerability, PK, immunogenicity and serum virus neutralizing activity.

Phase 1 Poster Information: (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Dose Selection Strategy
To support dose selection for Adagio’s global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half-life monoclonal antibodies in serum and key sites of viral replication in the respiratory tract. Adagio’s model adequately a priori predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagio’s Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE.

For the STAMP treatment trial, data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads. Further, for the EVADE prevention trial, data compiled to date suggest the 300 mg IM regimen has a projected ability to rapidly exceed target serum concentrations in the majority of simulated patients and to maintain potentially effective concentrations for up to 12 months.

Dose Selection Poster Information

  • (1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
  • (1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
  • (1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)

The STAMP and EVADE clinical trials are currently ongoing and enrolling patients globally. For more information, please visit clincialtrials.gov.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA application, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
[email protected]

Investor Contact:
Monique Allaire, THRUST Strategic Communications
[email protected]

Deputy President on vaccination drive in North West

Deputy President David Mabuza will on Friday launch the Vooma Vaccination Weekend Campaign in the North West, Bojanala Platinum District.

According to Presidency, the campaign is heeding President Ramaphosa’s call for every Minister, Premier and Mayor to convene at least one prominent event in every district in the country to support and encourage people to get vaccinated against Coronavirus.

“This includes providing information and taking the vaccination sites into communities and homes,” the Presidency said.

Furthermore, the Deputy President will also lead the “Return to Play – It’s in your Hands” of the Department of Sport, Arts and Culture at the Royal Bafokeng Stadium.

The focus, said the Presidency, is to partner with all sectors of society to increase the rate of vaccination in the country towards ensuring that SA attains the target of reaching population immunity by 31 December 2021.

The Deputy President has been visiting different communities to encourage the public who are still hesitant towards COVID-19 vaccines to get vaccinated in order to reduce chances of death, serious illness and hospitalisation from contracting Coronavirus.

“This is also to ensure that we return to normality and open up the economy,” the high office said.

Mabuza will be accompanied by Sport, Arts and Culture Minister Nathi Mtethwa, North West Premier Bushy Maape, Health Deputy Minister, Dr Sibongiseni Dhlomo and Bojanala Platinum District Mayor Maria Fetsang Molosiwa.

Source: South African Government News Agency

SIU implicates former Health Minister, high ranking Health officials in Digital Vibes saga

The Special Investigating Unit has found that the awarding of the infamous National Health Insurance (NHI) and COVID-19 communications contracts to Digital Vibes was “fraudulent, irregular” and “made a mockery of purported approved supply chain management” deviations that are allowed for government departments.

This was revealed in a report drawn up by the SIU following an investigation into the R150 million worth of contracts and service level agreements (SLAs) entered into between the National Department of Health (NDOH) and Digital Vibes.

The report was released by President Cyril Ramaphosa on Wednesday morning.

“[T]he procurement processes … were irregular and the subsequent contracts and/or SLAs … was/were void. In this regard, irregular expenditure amounting to approximately R150 million and fruitless and wasteful expenditure amounting to approximately between R72 million and R80 million was incurred by the NDOH,” the SIU said.

In the report, the unit said it had found wrongdoing on the part of, amongst others:

Then Acting Health Director General, Dr Anban Pillay, in the irregular appointment of Digital Vibes, expanding the mandate of its contract and requesting late approval from National Treasury for a deviation from regular supply chain channels.

Former Health Minister, Dr Zwelini Mkhize, for allegedly benefitting from repairs done at his home by Digital Vibes. His son is also alleged to have received R300 000 from Digital Vibes plus R160 000 paid towards the purchase of a car for him.

Digital Vibes and its owners for alleged fraud, paying of gratifications and failing to declare and pay company tax and VAT to the South African Revenue Service (SARS) and contraventions of several acts in the combatting of corruption.

A host of other National Health Department officials and other private individuals for their role in the scandal.

Findings against Mkhize

The report said evidence suggested that former health Minister Mkhize “mislead” the President and the nation when he denied that he or his family benefitted from the Digital Vibes deal.

“This denial was, objectively speaking, untrue, as the Minister’s son and the Minister himself had directly benefitted from Digital Vibes. The Minister indicated that he was at that stage not aware that he himself (via his property) or his son had benefitted in this regard and had been telling the truth as he knew it to be. However, the fact remains that the Minister’s denial was misleading to the public at large and the President,” the SIU said.

The unit further stated that it had found that he had gone against a cabinet memorandum instructing the GCIS (Government Communication and Information System) to drive the NHI media campaign and chided Dr Mkhize for approving the appointment of Digital Vibes to drive COVID-19 awareness campaigns despite a National Joint Operational and Intelligence Structure (NatJoints) decision to task GCIS to drive those campaigns.

“A Cabinet Memorandum…indicated that the GCIS would be responsible for the rollout of the NHI communication strategy. In the circumstances, it is astonishing that the Minister thereafter, contrary to the Cabinet Memorandum, allowed Digital Vibes to be appointed … in respect of the NHI media campaign. In fact, it can be argued that the Minister deliberately ignored a Cabinet decision.

“[T]he GCIS was again tasked…to do the COVID-19 awareness campaign for Government. Once again, it is inexplicable as to why the Minister would have allowed the ‘extension’ of the Digital Vibes SLA…to include the COVID-19 media campaign. It would have been far more cost-effective if the GCIS had rendered the required services,” the report said.

Former acting Health DG faces possible criminal prosecution

In the report, the SIU recommended that former Acting Director General of the NDOH during the COVID-19 media campaign and the NHI communications campaign, Dr Anban Pillay, be “criminally prosecuted for financial misconduct”.

“Dr Pillay was also one of, if not the main actor(s) within the NDOH who, by way of a SCM deviation…attempted to irregularly appoint Digital Vibes…for the provision of goods and/or services relating to allegedly urgent strategic communication solutions in respect of the NHI media campaign,” the unit said.

According to the unit, Dr Pillay was allegedly “one of the main actors” in a decision to make a closed tender process with only ten bidders chosen for the original NHI communications contract awarded in 2019.

Most of those chosen companies offered services that were either inappropriate or were not registered on government’s Central Supplier Database.

The only company who vied for the tender against Digital Vibes was communications company Brandswell which offered their services at more than half of the R141 million quoted by Digital Vibes.

“The TEC [Technical Evaluation Committee] of the NDOH disqualified Brandswell’s tender as it purportedly only had achieved a score of 59.2%, and not the minimum score of 60% functionality assessment. Digital Vibes received a 100% score from all the TEC members with regard to the functionality assessment. Brandswell was again in this manner irregularly and incorrectly disqualified from the NHI tender evaluation process,” the report said.

Dr Pillay was a member of the TEC at the time.

The unit also recommended disciplinary processes be instituted against him for gross misconduct, gross dereliction of duty and/or gross negligence.

Digital Vibes and its owners

The SIU also picked out the directors of Digital Vibes, Tahera Mather and Naadhira Mitha and its owner Radha Hariram for wrongdoing.

“Mather and … Mitha committed fraud in that they held out to the NDOH that Digital Vibes was tendering for the NHI media campaign contract, whereas in fact, [they] used Digital Vibes as a front in order to hide the fact that they were tendering for the contract and ‘disguised’ this, due to the fact that they were close associates of … [Mkhize], who was the Executive Authority of the NDOH,” the report said.

The unit said the three had also contravened at least two corruption busting laws.

“Digital Vibes… (at the instance of the Minister), direct family members of the Minister, former associates of the Minister and family members of former associates of the Minister contravened the provisions of section 3 read with sections 24 and 26 of the [Prevention and Combating of Corrupt Activities Act] in that they paid and received gratifications received gratifications resulting from the fact that the NDOH had irregularly and unlawfully awarded contract(s) to Digital Vibes.

“Furthermore, Digital Vibes… (at the instance of the Minister), contravened the provisions of section 2 of the Prevention of Organised Crime Act [related to money laundering],” the report found.

Source: South African Government News Agency

More than a million Gauteng residents dodge second jab

Gauteng Premier David Makhura says more than a million people in Gauteng have not gone back to receive their second jab of Pfizer’s COVID-19 vaccine.

He was speaking during a visit to the newly opened pop-up vaccine site at Khutsong in the Merafong municipality in the province’s West Rand on Wednesday.

Makhura highlighted that receiving the second jab of the vaccine gives you even more protection from getting severely ill if you contract COVID-19.

“We have over a million people who have taken their first dose of Pfizer whose days have come and passed for their second dose and they haven’t pitched at the vaccination site. I want to call on them to please go for their second dose. We know that the scientists say one dose of Pfizer protects you but the second dose makes you even much safer,” he said.

The premier encouraged those who are yet to be vaccinated, to do so before the expected fourth wave predicted to come later this year.

“Those who have not taken their first dose, we are saying to you, you are really playing a very dangerous game because should we get the fourth wave, you are not going to be in a very safe position. We want to reach more people ahead of the November elections where there will be lots of up and downs, ahead of the festive season and ahead of the fourth wave.

Meanwhile, Makhura revealed that at least 61% of the adult population living in the Merafong municipal area have received at least one dose of the Pfizer vaccine or the Johnson and Johnson vaccine.

“Those who are fully vaccinated are about 30% of that 61% which is above the national average. So we have come a very long way with this municipality on the vaccination programme.

Premier Makhura said the provincial government had been concerned about low vaccination turnout in the district but it is showing signs of more vaccine uptake.

“The West Rand as a district was doing very badly two months ago. We had to put lots of effort, lots of mobilisation. We had to release our mobile units. The story of successful [vaccination programmes] is when the local leaders, the local councillors and local community leaders go out and say…[they] will vaccinate. This has been the story here,” he said.

Source: South African Government News Agency

Minister Kubayi to hand over title deeds in Northern Cape

As part government’s ongoing engagements and visits to provinces to assess the state of housing delivery, Human Settlements Minister Mmamoloko Kubayi will on Thursday and Friday visit the Pixley Ka Seme and Sol Plaatje Local Municipalities in the Northern Cape.

The Minister, together with the Premier of Northern Cape, Dr Zamani Saul, will handover title deeds, do a sod turning for the construction of Hull Street Social Housing Project expected to yield 372 units upon completion and handover a house to 76-year-old Military Veteran, Daniel Mabe Sekgono of Ronaldsvlei.

“Minister Kubayi’ s visit also takes place in her capacity as the Champion of Pixley Ka Seme District Municipality and will provide a platform to engage with the executive leadership on the implementation of the District Development Model (DDM) in the province to improve service delivery,” the department said.

The DDM seeks to ensure maximum coordination and cooperation among all three spheres of government.

The delegation will include the MEC of Cooperative Governance, Human Settlements and Traditional Affairs, Bentley Vass, MEC of Finance, Economic Development and Tourism, Abraham Vosloo, MEC of Social Development, Nontobeko Vilakazi and Executive Mayor of Sol Plaatje Municipality, Cllr Patrick Mabilo.

Source: South African Government News Agency